Company Performance Metrics
Neose Technologies, Inc. operates under a plan of liquidation that was approved in January 2009. Previously, the company operated as a clinical-stage biopharmaceutical company that focused on the development of next-generation therapeutic proteins. The company’s products were developed based on the GlycoPEGylation technology that involved the use
of enzymes to attach PEG to carbohydrate structures on proteins. Its therapeutic protein candidates in development stage included GlycoPEG-GCSF, a phase-I completed product, for the treatment of neutropenia associated with myelosuppressive chemotherapy; and GlycoPEG-FVIIa for the treatment of bleeding episodes and for the prevention of bleeding during surgery or invasive procedures in patients with congenital hemophilia with inhibitors to coagulation factors VIII or IX. Neose Technologies, Inc. was founded in 1989 and is headquartered in Horsham, Pennsylvania
